Q1 Earnings Forecast for INSP Issued By Leerink Partnrs

Inspire Medical Systems, Inc. (NYSE:INSP) – Investment analysts at Leerink Partnrs raised their Q1 2025 earnings estimates for Inspire Medical Systems in a note issued to investors on Tuesday, February 11th. Leerink Partnrs analyst M. Kratky now forecasts that the company will post earnings of ($0.18) per share for the quarter, up from their prior forecast of ($0.25). The consensus estimate for Inspire Medical Systems’ current full-year earnings is $1.33 per share. Leerink Partnrs also issued estimates for Inspire Medical Systems’ Q2 2025 earnings at $0.46 EPS, Q3 2025 earnings at $0.60 EPS, Q4 2025 earnings at $1.25 EPS, FY2025 earnings at $2.14 EPS, FY2026 earnings at $3.28 EPS, FY2027 earnings at $4.27 EPS and FY2029 earnings at $6.80 EPS.

Inspire Medical Systems (NYSE:INSP) last released its quarterly earnings results on Monday, February 10th. The company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.41. Inspire Medical Systems had a net margin of 4.37% and a return on equity of 5.30%.

A number of other equities analysts have also issued reports on INSP. Royal Bank of Canada reiterated an “outperform” rating and set a $260.00 target price on shares of Inspire Medical Systems in a research report on Tuesday. Bank of America upgraded shares of Inspire Medical Systems from a “neutral” rating to a “buy” rating and upped their target price for the stock from $220.00 to $255.00 in a research report on Wednesday, November 20th. Morgan Stanley reduced their target price on shares of Inspire Medical Systems from $230.00 to $220.00 and set an “overweight” rating on the stock in a research report on Tuesday. Piper Sandler reduced their target price on shares of Inspire Medical Systems from $260.00 to $233.00 and set an “overweight” rating on the stock in a research report on Monday. Finally, Stifel Nicolaus reduced their target price on shares of Inspire Medical Systems from $200.00 to $190.00 and set a “hold” rating on the stock in a research report on Tuesday, January 21st. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $228.82.

Inspire Medical Systems Trading Up 0.1 %

Shares of INSP stock opened at $187.23 on Thursday. Inspire Medical Systems has a 1 year low of $123.00 and a 1 year high of $257.40. The firm’s 50 day moving average is $189.20 and its 200-day moving average is $191.36. The firm has a market capitalization of $5.61 billion, a price-to-earnings ratio of 174.98 and a beta of 1.32.

Institutional Investors Weigh In On Inspire Medical Systems

Several large investors have recently bought and sold shares of INSP. B. Metzler seel. Sohn & Co. Holding AG bought a new stake in shares of Inspire Medical Systems during the third quarter worth $1,929,000. Thrivent Financial for Lutherans increased its position in shares of Inspire Medical Systems by 39.7% during the third quarter. Thrivent Financial for Lutherans now owns 110,580 shares of the company’s stock worth $23,337,000 after acquiring an additional 31,444 shares in the last quarter. Allspring Global Investments Holdings LLC increased its position in shares of Inspire Medical Systems by 798.3% during the third quarter. Allspring Global Investments Holdings LLC now owns 267,852 shares of the company’s stock worth $56,530,000 after acquiring an additional 238,034 shares in the last quarter. Merit Financial Group LLC bought a new stake in shares of Inspire Medical Systems during the fourth quarter worth $313,000. Finally, Principal Financial Group Inc. increased its position in shares of Inspire Medical Systems by 3,812.6% during the third quarter. Principal Financial Group Inc. now owns 141,089 shares of the company’s stock worth $29,777,000 after acquiring an additional 137,483 shares in the last quarter. Institutional investors own 94.91% of the company’s stock.

Insider Activity at Inspire Medical Systems

In other Inspire Medical Systems news, CTO John Rondoni sold 583 shares of the company’s stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $170.49, for a total value of $99,395.67. Following the completion of the sale, the chief technology officer now owns 10,424 shares of the company’s stock, valued at approximately $1,777,187.76. This represents a 5.30 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 4.10% of the stock is currently owned by company insiders.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.